Patent: 10,620,210
✉ Email this page to a colleague
Summary for Patent: 10,620,210
| Title: | Aptamers and diagnostic methods for detecting the EGF receptor |
| Abstract: | The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3\' cap. In some embodiments, the 3\' cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5\'-end of the aptamer and the moiety is attached the 5\' end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore. |
| Inventor(s): | Bock; Chris (Denver, CO), Ayers; Deborah (Broomfield, CO), Nikrad; Malti P. (Boulder, CO), Gawande; Bharat Nathu (Lafayette, CO), Bertino; Jennifer C. (Arvada, CO), Sun; Weimin (Irvine, CA), Strom; Charles M. (San Clemente, CA), Park; Noh Jin (San Juan Capistrano, CA) |
| Assignee: | Quest Diagnostics Investments Incorporated (Wilmington, DE) Somalogic, Inc. (Boulder, CO) |
| Application Number: | 15/587,851 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,620,210
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2031-12-30 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2031-12-30 |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2031-12-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
